WO2022116139A1 - Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc - Google Patents
Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc Download PDFInfo
- Publication number
- WO2022116139A1 WO2022116139A1 PCT/CN2020/133860 CN2020133860W WO2022116139A1 WO 2022116139 A1 WO2022116139 A1 WO 2022116139A1 CN 2020133860 W CN2020133860 W CN 2020133860W WO 2022116139 A1 WO2022116139 A1 WO 2022116139A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sgrna
- endogenous
- nucleic acid
- expression
- mcherry
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 106
- 108091046869 Telomeric non-coding RNA Proteins 0.000 title claims abstract description 47
- 238000000034 method Methods 0.000 title claims abstract description 27
- 230000001413 cellular effect Effects 0.000 title abstract description 6
- 230000014509 gene expression Effects 0.000 claims abstract description 118
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 52
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 50
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 27
- 230000003834 intracellular effect Effects 0.000 claims abstract description 4
- 238000001514 detection method Methods 0.000 claims description 40
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 108700008625 Reporter Genes Proteins 0.000 claims description 14
- 108020004566 Transfer RNA Proteins 0.000 claims description 12
- 230000008685 targeting Effects 0.000 claims description 12
- 239000012190 activator Substances 0.000 claims description 11
- 101100447432 Danio rerio gapdh-2 gene Proteins 0.000 claims description 10
- 101150112014 Gapdh gene Proteins 0.000 claims description 10
- 238000013518 transcription Methods 0.000 claims description 7
- 230000035897 transcription Effects 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 6
- 108020005004 Guide RNA Proteins 0.000 claims description 5
- 108091006106 transcriptional activators Proteins 0.000 claims description 5
- 230000008519 endogenous mechanism Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 108091023045 Untranslated Region Proteins 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 11
- 230000002068 genetic effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 230000003915 cell function Effects 0.000 abstract description 2
- 230000002103 transcriptional effect Effects 0.000 abstract description 2
- 238000005259 measurement Methods 0.000 abstract 2
- 238000000691 measurement method Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 67
- 239000002243 precursor Substances 0.000 description 19
- 238000003780 insertion Methods 0.000 description 17
- 230000037431 insertion Effects 0.000 description 17
- 239000002773 nucleotide Substances 0.000 description 14
- 125000003729 nucleotide group Chemical group 0.000 description 14
- 238000011529 RT qPCR Methods 0.000 description 13
- 230000004069 differentiation Effects 0.000 description 11
- 101150087690 ACTB gene Proteins 0.000 description 10
- 238000003491 array Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 9
- -1 Nanog Proteins 0.000 description 6
- 108700023707 TUG1 Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108091006047 fluorescent proteins Proteins 0.000 description 6
- 102000034287 fluorescent proteins Human genes 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 108700039887 Essential Genes Proteins 0.000 description 5
- 108091007767 MALAT1 Proteins 0.000 description 5
- 101100516508 Mus musculus Neurog2 gene Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000024245 cell differentiation Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 101150010353 Ascl1 gene Proteins 0.000 description 4
- 101150099612 Esrrb gene Proteins 0.000 description 4
- 101100013967 Mus musculus Gata3 gene Proteins 0.000 description 4
- 102100038554 Neurogenin-2 Human genes 0.000 description 4
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 108091093018 PVT1 Proteins 0.000 description 3
- 101150026222 TUBB3 gene Proteins 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 108091033409 CRISPR Proteins 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 101100237015 Caenorhabditis elegans let-49 gene Proteins 0.000 description 2
- 108010042407 Endonucleases Proteins 0.000 description 2
- 102000004533 Endonucleases Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 101150113031 Jag1 gene Proteins 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 101100183449 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) med-7 gene Proteins 0.000 description 2
- 101150079815 Sema3a gene Proteins 0.000 description 2
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 2
- 101150111019 Tbx3 gene Proteins 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108091032955 Bacterial small RNA Proteins 0.000 description 1
- 101100223219 Borrelia burgdorferi (strain ATCC 35210 / B31 / CIP 102532 / DSM 4680) hup gene Proteins 0.000 description 1
- 101710172824 CRISPR-associated endonuclease Cas9 Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 101100361074 Drosophila melanogaster RNaseZ gene Proteins 0.000 description 1
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 101150013707 HBB gene Proteins 0.000 description 1
- 102100032606 Heat shock factor protein 1 Human genes 0.000 description 1
- 101000867525 Homo sapiens Heat shock factor protein 1 Proteins 0.000 description 1
- 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 1
- 102000055601 Nanog Homeobox Human genes 0.000 description 1
- 108700026371 Nanog Homeobox Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102100029244 RNA-binding protein 15 Human genes 0.000 description 1
- 102000002150 RNase Z Human genes 0.000 description 1
- 108010001294 RNase Z Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000004167 Ribonuclease P Human genes 0.000 description 1
- 108090000621 Ribonuclease P Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 230000005966 endogenous activation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000002304 esc Anatomy 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- VOVZXURTCKPRDQ-CQSZACIVSA-N n-[4-[chloro(difluoro)methoxy]phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-5-yl)pyridine-3-carboxamide Chemical class C1[C@H](O)CCN1C1=NC=C(C(=O)NC=2C=CC(OC(F)(F)Cl)=CC=2)C=C1C1=CC=NN1 VOVZXURTCKPRDQ-CQSZACIVSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004031 neuronal differentiation Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un promoteur sensible au ARNsg, un système de mesure contenant le promoteur sensible au ARNsg et utilisé pour détecter l'acide nucléique endogène cellulaire, et un procédé de mesure correspondant. Au moyen du système ou du procédé de mesure, un gène endogène ayant un très faible niveau d'expression intracellulaire peut être détecté de manière fiable, et l'activité transcriptionnelle d'un long ARN non codant (ARNlnc) souvent sous-exprimé peut également être surveillée dans des cellules vivantes. En outre, grâce au procédé, un signal endogène peut être amplifié pour visualiser les processus dynamiques d'expression d'un gène à faible abondance et d'un ARNnlc dans les cellules, et une plate-forme puissante est fournie pour détecter l'activité d'un élément génétique endogène, et sa fonction cellulaire potentielle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/133860 WO2022116139A1 (fr) | 2020-12-04 | 2020-12-04 | Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2020/133860 WO2022116139A1 (fr) | 2020-12-04 | 2020-12-04 | Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022116139A1 true WO2022116139A1 (fr) | 2022-06-09 |
Family
ID=81852736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/133860 WO2022116139A1 (fr) | 2020-12-04 | 2020-12-04 | Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022116139A1 (fr) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105517579A (zh) * | 2013-07-10 | 2016-04-20 | 哈佛大学校长及研究员协会 | 用于RNA向导的基因调节和编辑的正交Cas9蛋白 |
| WO2017040793A1 (fr) * | 2015-09-01 | 2017-03-09 | Dana-Farber Cancer Institute Inc. | Systèmes et procédés de sélection de brins ciblant l'arng pour la localisation de cas9 |
| CN107722125A (zh) * | 2017-09-28 | 2018-02-23 | 中山大学 | 一种高效的人工转录激活因子dCas9‑TV及其编码基因与应用 |
| CN110777159A (zh) * | 2019-12-03 | 2020-02-11 | 苏州缔因安生物科技有限公司 | 一种基于CRISPR-Cas9的核酸检测系统及其应用 |
-
2020
- 2020-12-04 WO PCT/CN2020/133860 patent/WO2022116139A1/fr active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105517579A (zh) * | 2013-07-10 | 2016-04-20 | 哈佛大学校长及研究员协会 | 用于RNA向导的基因调节和编辑的正交Cas9蛋白 |
| WO2017040793A1 (fr) * | 2015-09-01 | 2017-03-09 | Dana-Farber Cancer Institute Inc. | Systèmes et procédés de sélection de brins ciblant l'arng pour la localisation de cas9 |
| CN107722125A (zh) * | 2017-09-28 | 2018-02-23 | 中山大学 | 一种高效的人工转录激活因子dCas9‑TV及其编码基因与应用 |
| CN110777159A (zh) * | 2019-12-03 | 2020-02-11 | 苏州缔因安生物科技有限公司 | 一种基于CRISPR-Cas9的核酸检测系统及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| FANG KAILUN, YANG HUI: "Advances and applications of CRISPR/Cas toolbox", SCIENCE BULLETIN, vol. 65, no. 11, 1 April 2020 (2020-04-01), CN , pages 973 - 990, XP055937416, ISSN: 0023-074X, DOI: 10.1360/TB-2019-0806 * |
| FILLIP PORT, BULLOCK SIMON L: "Augmenting CRISPR applications in Drosophila with tRNA-flanked sgRNAs", NATURE METHODS, vol. 13, no. 10, 1 October 2016 (2016-10-01), New York, pages 852 - 854, XP055344550, ISSN: 1548-7091, DOI: 10.1038/nmeth.3972 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Schumann et al. | Multiple links between 5-methylcytosine content of mRNA and translation | |
| Liu et al. | The RNA m6A reader YTHDC1 silences retrotransposons and guards ES cell identity | |
| Tambe et al. | RNA binding and HEPN-nuclease activation are decoupled in CRISPR-Cas13a | |
| Tran et al. | Differential toxicity of nuclear RNA foci versus dipeptide repeat proteins in a Drosophila model of C9ORF72 FTD/ALS | |
| Sugimoto et al. | hiCLIP reveals the in vivo atlas of mRNA secondary structures recognized by Staufen 1 | |
| Kalimutho et al. | Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer | |
| Lee et al. | Regenerating zebrafish fin epigenome is characterized by stable lineage-specific DNA methylation and dynamic chromatin accessibility | |
| Kumar et al. | A high-throughput method for Illumina RNA-Seq library preparation | |
| WO2021168261A1 (fr) | Capture de cibles génétiques à l'aide d'une approche d'hybridation | |
| JP2023529611A (ja) | ゲノム編集のための組成物及び方法 | |
| Wissink et al. | High-throughput discovery of post-transcriptional cis-regulatory elements | |
| Li et al. | A DNA ligase required for active DNA demethylation and genomic imprinting in Arabidopsis | |
| US20210262034A1 (en) | Methods for identifying and using small rna predictors | |
| Cardiello et al. | Heat shock causes a reversible increase in RNA polymerase II occupancy downstream of mRNA genes, consistent with a global loss in transcriptional termination | |
| JP2021520205A (ja) | 機能的なＩｎｃＲＮＡをスクリーニングおよび同定するための方法 | |
| Rivas et al. | The herpes simplex virus 1 protein ICP4 acts as both an activator and a repressor of host genome transcription during infection | |
| Siva et al. | Molecular assays for the detection of microRNAs in prostate cancer | |
| Kirchhoff et al. | Gene expression variability between randomly and targeted transgene integration events in tobacco suspension cell lines | |
| WO2022116139A1 (fr) | Procédé de mesure de niveaux de gène de faible abondance endogène cellulaire et de arnlnc | |
| Bolouri et al. | A B-cell developmental gene regulatory network is activated in infant AML | |
| US20220127611A1 (en) | Methods of modulating rna translation | |
| WO2004053106A2 (fr) | Sites regulateurs profiles utiles pour le controle de l'expression genique | |
| CA3211847A1 (fr) | Arn circulaires pour le diagnostic de la depression et la prediction de la reponse a un traitement antidepresseur | |
| Bae et al. | CRISPR-Mediated Knockout of Long 3′ UTR mRNA Isoforms in mESC-Derived Neurons | |
| Dodel et al. | TREX reveals proteins that bind to specific RNA regions in living cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20963985 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20963985 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20963985 Country of ref document: EP Kind code of ref document: A1 |